Insulet’s Omnipod 5 Receives the US FDA’s Clearance for Type 1 Diabetes in Children Aged ≥2 Years
Shots:
- The company received the US FDA clearance for Omnipod 5, the first tubeless automated insulin delivery system for individuals aged ≥2yrs. with T1D
- The system works in conjunction with a compatible smartphone & Dexcom G6 CGM system to automatically adjust insulin & assist guard against high & low glucose levels. The tubeless pod improved with SmartAdjust technology, the Omnipod 5 mobile app with its built-in SmartBolus calculator, and the Dexcom G6 CGM
- The results showed that Omnipod 5 could improve time in range, and reduce HbA1c & time in hypoglycemia (<70 mg/dL) in young children aged 2 – 5.9yrs. with T1D while parents reported improved sleep quality as assessed by PSQI, published in Diabetes Care
Ref: Insulet | Image: Insulet
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
